Elsevier's Drug Database Now Delivers the Most Accurate and Thorough Drug Dose Screening to Reduce Adverse Events and Unnecessary Alerts

PHILADELPHIA, July 10, 2018 /PRNewswire/ --

Expanded content in Gold Standard Drug Database supports health professionals and healthcare organizations in preventing clinically and financially harmful drug dosing errors 

Elsevier, the information analytics business specializing in science and health, and part of RELX Group, today announced the expansion of medication dose checking capabilities in its Gold Standard Drug Database.

The dose checking content protects against excessive, inadequate and/or potentially dangerous doses to ensure optimal delivery of the patient's medication. Available within the clinical decision support suite of Gold Standard Drug Database, the dose checking content is now the most robust in the industry, including:

• Minimum/maximum daily doses for all populations, from premature neonates to geriatrics
• Two maximum daily doses: an FDA-approved maximum dose and a literature-validated maximum dose
• Maximum single dose and daily dose screening
• Loading dose and routine dose screening
• Dose checking based on critical characteristics when appropriate, including:
  • patient weight or body surface area
  • renal function, based on creatinine clearance
  • hepatic function, based on Child-Pugh score
• Dose checking for non-solid dosage forms (such as inhalers), including measured delivery quantity
• Dose ranges for single injections and continuous infusions
• Lifetime maximum dosage alert
• Opioid dose screening based on the patient's medication tolerance (i.e., experienced versus naïve)
• Pediatric dose checking, including for ages 6 and under, based on quality evidence

Gold Standard Drug Database exclusively offers TRUE Daily Updates^tm to deliver advanced drug data and decision support for integration into health systems and applications. In tandem with evidence-based, peer-reviewed content, intelligent screening tools in the Gold Standard Drug Database protect against false negative alerts that can lead to unsafe drug therapy decisions, and false positive alerts that cause dangerous alert fatigue and overrides. These safeguards are designed to help reduce the nearly 700,000 emergency department visits and 100,000 hospitalizations each year due to adverse drug events (U.S. Agency for Healthcare Research and Quality, ahrq.gov).

About Elsevier 

Elsevier is a global information analytics business that helps institutions and professionals advance healthcare, open science and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support and professional education, including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 38,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com

Media contact
Christopher Capot, Global Communications
Elsevier
+1-917-704-5174
[email protected]